Results 171 to 180 of about 10,730,120 (241)

Development of a Patient-Reported Outcome Measure (PROM) in Bony Facial Trauma Patients. [PDF]

Laryngoscope Investig Otolaryngol
Curran K, Panzer A, Guterbock T, Park S, Oyer S.   +4 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Translating scores into meaning: a co-produced forum for patient-reported outcome measure interpretation in pediatric congenital heart disease. [PDF]

Res Involv Engagem
Willems J, Eyrich A, Terjung J, Stricker A, König V, Ringwald A, Huth P, Stiller B, Langer T, Zürn C.   +9 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Multicentre validation of a patient-reported outcome measure for functional movement disorders. [PDF]

J Neurol Neurosurg Psychiatry
Michaelis R, Hagedorn L, Weissbach A, van Riesen C, Zeuner KE, Schmidt T, Bolte C, Bernsdorff F, Löw MJ, Gless CA, Reincke A, Sykora D, LaFaver K, Lehn AC, Kleinschnitz C, Seliger C, Popkirov S.   +16 more
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Development and validation of PEYRO-Q: a novel multidimensional patient-reported outcome measure for Peyronie's disease. [PDF]

Sex Med
Cocci A, Lo Re M, Pezzoli M, Romero-Otero J, Salamanca JIM, Mourel-Journel N, Neuville P, Faix A, Ward S, Van Renterghem K, Hatzichristodoulou G, Osmonov D, Ralph D, Cadenar A, Falcone M, Russo GI, Bettocchi C, Cacciamani GE, Mondaini N, Skrodzka M, Pozzi E, Salonia A.   +21 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling. [PDF]

J Med Internet Res
Atter M, Bullen A, Cresswell K, Hall PS.
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source